

REMARKS

Introductory Matters

Claims 1-21, 23-27, and 29-39 are pending in this application. Applicants acknowledge with appreciation that the Examiner has allowed claims 1-20, 23-26, 31, 34, 36, and 38.

The Amendments

Applicants have amended claim 18 to no longer refer to claims 1-16.

Applicants have cancelled claims 29, 32, 33, 35, 37, and 39 to further prosecution.

The Office Action

35 U.S.C. § 112, first paragraph

Claims 29, 32-33, 35, 37, and 39 stand rejected under 35 U.S.C. § 112, first paragraph as lacking enablement. The Examiner contends that the specification "while being enabling for the treatment of specific disease[s] such as colon cancer, breast cancer, stomach cancer, ovarian cancer or diabetes; inhibiting specific kinases, Aurora-2, GSK-3, Src, ERK-2 or AKT" it is not enabling for all the recited diseases. Applicants disagree. Nevertheless, to expedite prosecution, applicants have cancelled claims 29, 32-33, 35, 37, and 39 thus obviating these rejections.


The Objections

Claims 18, 21, 27, 29, and 30 stand objected to "as being in improper form because a multiple dependent claim cannot depend from any other multiple dependent claim." Applicants have amended claim 18 to delete the recitation of "claims 1-16" thus obviating these objections.

Conclusion

Accordingly, applicants request that the Examiner enter the above amendments, consider the foregoing remarks, and allow the pending claims to issue.

Respectfully submitted,



Lisa A. Dixon
Registration No. 40,995
Attorney for Applicants
VERTEX PHARMACEUTICALS INCORPORATED
130 Waverly Street
Cambridge, Massachusetts 02139
Telephone: (617) 444-6396
Facsimile: (617) 444-6438